# Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

> **NCT05933278** · PHASE2 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 150 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 Subunit Recombinant Protein Vaccine

## Key facts

- **NCT ID:** NCT05933278
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-25
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-09-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933278, "Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05933278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*